What are the dosing and monitoring guidelines for desmopressin (DDAVP) in children with primary monosymptomatic nocturnal enuresis and in patients with central diabetes insipidus?

DDAVP Guidelines

For children with primary monosymptomatic nocturnal enuresis, start with oral desmopressin 0.2 mg at bedtime, titrating up to 0.6 mg as needed, with strict fluid restriction (≤200 mL evening intake), while for central diabetes insipidus, begin with 0.05 mg twice daily and titrate to 0.1-0.8 mg daily in divided doses based on antidiuretic response. 1, 2

Primary Monosymptomatic Nocturnal Enuresis

Dosing Protocol

• Initial dose: 0.2 mg at bedtime for children ≥6 years 2
• Timing:
  • Standard tablets: 1 hour before sleep (maximum effect at 1-2 hours) 1
  • Oral melt tablets: 30-60 minutes before bedtime 1
• Titration: Increase to 0.4 mg, then 0.6 mg if needed to achieve dryness 2, 3
• Dose is NOT weight-based - same dosing regardless of age or body weight 1

Critical Safety Monitoring

Fluid restriction is mandatory to prevent water intoxication, hyponatremia, and seizures:

• Evening fluid intake: ≤200 mL (6 ounces) from 1 hour before dose until morning (minimum 8 hours) 1, 2
• Contraindication: Polydipsia 1
• Avoid nasal spray formulation - higher risk of hyponatremia complications 1

Treatment Strategy

• Effect is immediate - no titration period needed to assess response 1
• Options: Daily use OR intermittent (important nights only) 1
• If daily therapy chosen: Regular short drug holidays to reassess ongoing need 1
• Expected response: 30% complete responders, 40% partial responders 1

Best Candidates

Desmopressin works best in children with:

• Nocturnal polyuria (>130% expected bladder capacity for age) 1
• Normal bladder function (maximum voided volume >70% expected capacity) 1
• Failed or unlikely to comply with alarm therapy 1

Central Diabetes Insipidus

Dosing Protocol

• Starting dose: 0.05 mg (½ of 0.1 mg tablet) twice daily 1, 2
• Target range: 0.1-0.8 mg daily in divided doses 1, 2
• Maximum: 1.2 mg daily divided into 2-3 doses 1
• Dose is NOT weight-based in standard practice 1

However, recent pediatric data suggests weight-based dosing may optimize outcomes:

• Average effective dose: 474 ± 222 mcg/m² daily 4
• For children 1-5 years who remain symptomatic: Consider 50 mcg as initial dose 5

Monitoring Parameters

• Adequate duration of sleep (no nocturia)
• Adequate water turnover (not excessive)
• Adjust each dose separately for diurnal rhythm 2
• Fluid restriction required 2

Transition from Intranasal Therapy

Begin oral tablets 12 hours after last intranasal dose 2

Special Populations

Pediatric Considerations (Age <5 years)

• Start at 0.05 mg to prevent hyponatremia and seizures 2
• Requires careful fluid intake restrictions with family education 2
• Younger children need more careful monitoring due to higher hyponatremia risk 2

Geriatric Patients

• Start at low end of dosing range 2
• Contraindicated if creatinine clearance <50 mL/min 2
• Higher risk of toxic reactions due to renal excretion 2
• Requires careful fluid restriction counseling 2

Common Pitfalls to Avoid

1. Water intoxication: Most serious complication - enforce strict evening fluid limits 1
2. Using nasal spray for enuresis: Removed indication in many countries due to higher hyponatremia risk 1
3. Ignoring drug holidays: Necessary to assess ongoing need and prevent tolerance 1
4. Treating during acute illness: Interrupt therapy during infections, fever, vomiting, diarrhea, or hot weather with increased fluid needs 2
5. Inadequate timing: Tablets must be taken 1 hour before sleep for optimal effect 1

Combination Therapy

When standard desmopressin fails in enuresis:

• Add anticholinergics (oxybutynin 5 mg, tolterodine 2 mg, or propiverine 0.4 mg/kg at bedtime) if detrusor overactivity present 1
• Combination with alarm therapy may increase children achieving 14 consecutive dry nights (RR 1.26) 6
• Useful in approximately 40% of therapy-resistant children 1

Efficacy Expectations

Nocturnal Enuresis

• Reduces wet nights by 27-40% depending on dose 3
• 44% achieve ≥50% reduction in wet nights at lower doses (0.2-0.4 mg) 3
• Linear dose-response relationship from 0.2-0.6 mg 3, 6

Safety Profile

Desmopressin is generally safe with low incidence of side effects 7:

• Most common: Mild rhinitis, pharyngitis, headache, increased cough 3
• Serious: Hyponatremia with seizures (preventable with fluid restriction) 1
• Safe for use up to several years 1